Durect and Nycomed To Collaborate On Anesthetic Posidur In $202 Mil. Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Durect expects to add 100 to 150 sales reps to market the drug in the U.S.
You may also be interested in...
Durect Reports Positive Phase IIb Results For Posidur In Post-Op Hernia Pain
Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.
Durect Reports Positive Phase IIb Results For Posidur In Post-Op Hernia Pain
Posidur, co-developed with Nycomed, has the potential to become a more than $2 billion opportunity, Durect CFO tells “The Pink Sheet” DAILY.
Nycomed/Altana Merger Reflects “Strategic” Pressures On Mid-Size Firms
European firms reach $5.4 bil. deal.